The loss of HLA-class I antigen expression on cell surface has implications for the associative recognition of antigenic tumor cells by cytotoxic T-lymphocytes. We investigated the expression of HLA-antigens (class I and II) in ovarian carcinoma cells. For labeling the cell membran antigen the immunoperoxidase-antiperoxidase slide assay (IPSA) and monoclonal antibodies were used. From 9 solid tumor specimens two cases expressed in all cells HLA-antigens, 7 tumors showed a remarkable variability of positive and negative cells. No HLA-negativ cells were seen. In contrast from 10 cases of malignant effusions 4 cases were completely HLA-negative, 4 showed positive and negative cells surfaces, and 2 showed 100% HLA-positive cells. These 2 patients whose tumor cells were labelled completely HLA-positive, CEA-negative and partially Transferrinreceptor-positive showed an unexpected good Clinical course. There was no correlation between the expression of HLA-antigens and the histology or the grade of differentiation. In 2 cases with simultaneous testing of primary tumors, abdominal metastases, and the ascites cells an increasing loss of HLA-expression from primary tumor via the abdominal metastasis to the ascites cells was seen. Our findings support the idea of an immunoselection of tumor cell clones. Further investigations must prove the prognostic meaning of HLAexpression in human ovarian cancer cells. Courses were administered in four weekly intervalls provided that the pts had recovered from myolotoxic side effects. Pts who had more than 6 weeks between courses will go off study. For evaluation of response the WHO criteria will be used. 5 pts had progressive disease after one cycle and died within 3 months. In the remaining 11 pts, I pt with CR, I pt with PR and I pt with stabilisation of disease (NC) were observed, 8 pts receiving more than 2 cycles showed no response (PD). Toxic side effects: In 39 cycles administered leukopenia (WBC<2000) occurred in 85% (33/39), thrombopenia (plat~75000) in 64% (27/39) and anaemia in 82%. Nausea and vomiting were less severe as shown by treatment with cisplatin but were also observed. In I pt nephrotoxic side effects were observed (Cr > 1,5). Reduction of dosage were performed in 18 of 39 cycles. In conclusion our preliminary analysis demonstrate, that carboplatinum has some activity in OC pts refraktory to standard dose cisplatin but has also dose limiting haematological toxicities. Carboplatinum is relativly free of nephro-, neuro-and ototoxicity.
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Ova 12 SIGNIFICANCE OF INIRAOPERAIIVE PERIIONEALCYIOLOGICAL FINDINGS IN CASES OF MALIGNANI OVARIAN IUMOURS
A. G~ppinger, M. Hilgarth, A. Pileiderer 7eking into account the histological type, aseites or peritoneal fluid was cytologically investigated in 259 m~ lignmnt ovarian tumours primarily in stage Ili. 62,5 % were classified as positive, 2,3 % as unclear and only 2,7 % were insufficient. In the cases of obvious per~ tonemlcarcinosis (n=175) the rate o• accuracy was even 75%. lhere was no difterence with regard to the histological type but s suprisingly high rate of accuracy concerning 13 unclassified tumours, lhus a second investigation took 1~ to account the degree of differentiation and the clinical stage of 103 patients with serous adenocereinoma o• the ovary. 133 surgical treatments (70 initial laparotomies end 63 second look laparotomzes) produced 107 positive histological findings. In 26 second look laparotomies there was histologically no evidence o~ disease, In none o• the 26 cases peritonealcytology was false positive, On the other hand, 66,3 % of the t07 histological positive cases were found to be peritonealcytologically positive too. In undi~• carcinomas the rate of accuracy ranging 77,4 % was notably higher comparing the 37,5 % of the well differentiated carcinomas, laking into account the macroscopical findings it was evident that this does not merely result from varying tumourvolumes. lhe cases os positive peritonealcytology without obvious peritonealcarcinosis at the initial surgical treatment and macroscopically negativ finding at the second look laparo~ tomy (8 of 22) support the signiiicance of this method with regard to staging and therapy~planing.
Univ.-Frauenklinik, Hugstetterstr.55, g 7800 Freiburg FRG Ova 14 PHASE 11 STUDY OF CARBOPLATINUM/CYCLOPHOSPHAMIDE COMBINA-TION CHEMOTHERAPY FOR OVARIAN CANCER H.G. Meerpohl, J. Pohl and A. Pfleiderer Carboplatinum (CBDCA,JM-8) is a new but less tocix platinum analogue which seems at least as active against various tumors as the parent compound. Here is reported our initial experience with a phase II study of JM-8 in combination with cyclophosphamide in patients with advanced ovarian cancer. Between october 1984 and september 1985 23 pts suffering from histologically proved epithelial tumors were entered in this trial. When categorized by prognostic factors, 18pts(78%) showed stage III and 5pts(22%) stage IV of disease. Small residual tumor (<2cm) was observed in 12pts(52%) whereas 11pts(48%) had a large unfavorable postoperative tumorbulk (>2cm). With regard to histologic grade, 15pts(65%) had poorly differentiated tumors (grade 3). The treatment-scheme consisted of a fixed dose of cyclophosphamide (600mg/m 2 iv dl) combined with increasing doses of carboplatinum (200-400mg/m 2 iv dl). There was no pre-or posthydration. The first results which had been observed so far are described below: JM-8/CYC CR PR NC PD NOT EVALUABLE 200/600 I 2 3 300/600 I 3 I 3 350/600 I I -5 400/600 I I The extent of hematologic toxic effects must be paid attention to because leucopenia (~ 1000/mm 3) and/or thrombocytopenia (<25000/mm 3) occured in 16 out of 109 treatment-courses. The myelosuppression however was in general rapidly reversable. The nonhematological toxicity which had been registered was encouragingly low. At the moment our impression is, that carboplatinum in this patient group is tolerated more than cisplatinum. The final analysis of the still ongoing trial should clarify the optimal dose of JM-8 in combination with cyclophosphamide and the degree of activity at each dose level, Universit~ts-Frauenklinik Freiburg HugstetterstraBe 55, D-7800 Freiburg
